Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based Trivalent Subunit Influenza Virus Vaccines in Subjects Ages ≥4 Years to < 18 Years
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Alabama
-
Huntsville, Alabama, Yhdysvallat, 35802
-
Mobile, Alabama, Yhdysvallat, 36608
-
-
Arizona
-
Chandler, Arizona, Yhdysvallat, 85224
-
Mesa, Arizona, Yhdysvallat, 85206
-
Mesa, Arizona, Yhdysvallat, 85213
-
-
Arkansas
-
Harrisburg, Arkansas, Yhdysvallat, 72452
-
Jonesboro, Arkansas, Yhdysvallat, 72401
-
-
California
-
Anaheim, California, Yhdysvallat, 92804
-
Anaheim, California, Yhdysvallat, 92801
-
Downey, California, Yhdysvallat, 90241
-
Garden Grove, California, Yhdysvallat, 92844
-
Modesto, California, Yhdysvallat, 95350
-
Paramount, California, Yhdysvallat, 90723
-
Sacramento, California, Yhdysvallat, 95816
-
San Diego, California, Yhdysvallat, 92103-6204
-
San Francisco, California, Yhdysvallat, 94102
-
Santa Rosa, California, Yhdysvallat, 95405
-
West Covina, California, Yhdysvallat, 91790
-
-
Colorado
-
Colorado Springs, Colorado, Yhdysvallat, 80907
-
Denver, Colorado, Yhdysvallat, 80246
-
Denver, Colorado, Yhdysvallat, 80249
-
Thornton, Colorado, Yhdysvallat, 80233
-
-
Florida
-
Boca Raton, Florida, Yhdysvallat, 33432
-
Lake Mary, Florida, Yhdysvallat, 32746
-
Melbourne, Florida, Yhdysvallat, 32935
-
Miami Beach, Florida, Yhdysvallat, 33141
-
Opa Locka, Florida, Yhdysvallat, 33055
-
Pinellas Park, Florida, Yhdysvallat, 33781
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30338
-
Marietta, Georgia, Yhdysvallat, 30062
-
Woodstock, Georgia, Yhdysvallat, 30189
-
-
Idaho
-
Boise, Idaho, Yhdysvallat, 83642
-
-
Illinois
-
Peoria, Illinois, Yhdysvallat, 61602
-
-
Indiana
-
Mishawaka, Indiana, Yhdysvallat, 46545
-
-
Iowa
-
Council Bluffs, Iowa, Yhdysvallat, 51503
-
-
Kansas
-
Newton, Kansas, Yhdysvallat, 67114
-
Wichita, Kansas, Yhdysvallat, 67207
-
Wichita, Kansas, Yhdysvallat, 67010
-
-
Kentucky
-
Lexington, Kentucky, Yhdysvallat, 40509
-
Louisville, Kentucky, Yhdysvallat, 40291
-
-
Louisiana
-
Metairie, Louisiana, Yhdysvallat, 70006
-
-
Missouri
-
Kansas City, Missouri, Yhdysvallat, 64114
-
St. Louis, Missouri, Yhdysvallat, 63141
-
-
Nebraska
-
Bellevue, Nebraska, Yhdysvallat, 68005
-
Fremont, Nebraska, Yhdysvallat, 68025
-
Omaha, Nebraska, Yhdysvallat, 68114
-
Omaha, Nebraska, Yhdysvallat, 68134
-
-
Nevada
-
Las Vegas, Nevada, Yhdysvallat, 89104
-
-
New York
-
Binghamton, New York, Yhdysvallat, 13901
-
-
North Carolina
-
Wilmington, North Carolina, Yhdysvallat, 28401
-
-
Ohio
-
Akron, Ohio, Yhdysvallat, 44311
-
Cincinnati, Ohio, Yhdysvallat, 45249
-
Cleveland, Ohio, Yhdysvallat, 44106
-
Cleveland, Ohio, Yhdysvallat, 44122
-
Dayton, Ohio, Yhdysvallat, 45414
-
Dayton, Ohio, Yhdysvallat, 45406
-
Kettering, Ohio, Yhdysvallat, 45429
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Yhdysvallat, 73112
-
Oklahoma City, Oklahoma, Yhdysvallat, 73103
-
Tulsa, Oklahoma, Yhdysvallat, 74127
-
-
Pennsylvania
-
Erie, Pennsylvania, Yhdysvallat, 16505
-
Erie, Pennsylvania, Yhdysvallat, 16508
-
Hermitage, Pennsylvania, Yhdysvallat, 16148
-
Sellersville, Pennsylvania, Yhdysvallat, 18960
-
Upper St. Clair, Pennsylvania, Yhdysvallat, 15241
-
-
South Carolina
-
Anderson, South Carolina, Yhdysvallat, 29621
-
Charleston, South Carolina, Yhdysvallat, 29403
-
Mt. Pleasant, South Carolina, Yhdysvallat, 29464
-
-
Tennessee
-
Bristol, Tennessee, Yhdysvallat, 37620
-
Jefferson City, Tennessee, Yhdysvallat, 37760
-
Lebanon, Tennessee, Yhdysvallat, 37087
-
Nashville, Tennessee, Yhdysvallat, 37203
-
-
Texas
-
Austin, Texas, Yhdysvallat, 78705
-
Dallas, Texas, Yhdysvallat, 75231
-
Fort Worth, Texas, Yhdysvallat, 76107
-
Fort Worth, Texas, Yhdysvallat, 76135
-
Round Rock, Texas, Yhdysvallat, 78681
-
San Angelo, Texas, Yhdysvallat, 76904
-
San Antonio, Texas, Yhdysvallat, 78229
-
-
Utah
-
Draper, Utah, Yhdysvallat, 84020
-
Layton, Utah, Yhdysvallat, 84041
-
Salt Lake City, Utah, Yhdysvallat, 84121
-
Salt Lake City, Utah, Yhdysvallat, 84109
-
Salt Lake City, Utah, Yhdysvallat, 84124
-
South Jordan, Utah, Yhdysvallat, 84095
-
West Jordan, Utah, Yhdysvallat, 84088
-
-
Virginia
-
Burke, Virginia, Yhdysvallat, 22015
-
Charlottesville, Virginia, Yhdysvallat, 22902
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Male or female aged 4 years to less than 18 years of age.
- Individual who had a parent or guardian who could give written informed consent after understanding the nature of the study and comply with study procedures and were available for follow-up.
- If the individual was of an age where, according to local regulations, informed assent is required, that individual had provided assent to participate in the study.
Exclusion Criteria:
- Individuals recently vaccinated against influenza
- Subjects with contraindications to receive influenza vaccine
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: QIVc (≥4 to <18 years)
Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
|
Novartis Investigational Quadrivalent Vaccine
|
|
Active Comparator: TIV1c (≥4 to <18 years)
Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage ("B1" strain) recommended for 2013-2014 season
|
Licensed Influenza Vaccine
|
|
Active Comparator: TIV2c (≥4 to <18 years)
Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage ("B2" strain) recommended for 2013-2014
|
Novartis Investigational Vaccine
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Geometric Mean Titre (GMT) in Subjects After Receiving One or Two Doses of Either QIVc, TIV1c or TIV2c
Aikaikkuna: Day 1,Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity of QIVc to comparator TIV1c (For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c) was assessed in terms of GMT in subjects (Previously vaccinated and Not previously vaccinated) measured by hemagglutination inhibition (HI) assay, three weeks after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c. Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c or TIV2c /GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5. |
Day 1,Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Percentages of Subjects Achieving Seroconversion After One or Two Doses of Either QIVc, TIV1c or TIV2c
Aikaikkuna: Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity of QIVc to comparator TIVc (For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c) was assessed in terms of number (%) of subjects (Previously vaccinated and Not previously vaccinated) showing seroconversion or significant increase (at least a 4-fold increase in HI titer in subjects seropositive at baseline [i.e., HI titer ≥1:10 at Day 1] ) in HI antibody titers, three weeks after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c Seroconversion was defined in subjects seronegative at baseline (i.e., HI titer <1:10 at Day 1) as postvaccination HI titer ≥1:40, and defined in subjects seropositive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
|
Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentages of Subjects Achieving Seroconversion After One or Two Doses of Either QIVc, TIV1c or TIV2c in ≥4 to <18 Years
Aikaikkuna: Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity was assessed in terms of number (%) of subjects (Previously vaccinated and Not previously vaccinated) showing seroconversion or significant increase in HI antibody titers, three weeks after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c Seroconversion was defined in subjects seronegative at baseline (i.e., HI titer <1:10 at Day 1) as postvaccination HI titer ≥1:40, and defined in subjects seropositive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer. The Center for Biologics Evaluation, Research, and Review (CBER) criterion for an adult population is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40% |
Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Percentages of Subjects Achieving HI Titer ≥1:40 After One or Two Doses of Either QIVc, TIV1c or TIV2c in ≥4 to <18 Years
Aikaikkuna: Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity was assessed in terms of number (%) of subjects (Previously vaccinated and Not previously vaccinated) showing HI titer ≥1:40, three weeks after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c. The CBER criterion for adult population was that the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70% |
Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Percentages of Subjects Achieving Seroconversion After One or Two Doses of Either QIVc, TIV1c or TIV2c in ≥4 to <18 Years
Aikaikkuna: Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity was assessed in terms of number (%) of subjects (Previously vaccinated and Not previously vaccinated) showing seroconversion or significant increase in HI antibody titers, three weeks after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c Seroconversion was defined in subjects seronegative at baseline (i.e., HI titer <1:10 at Day 1) as postvaccination HI titer ≥1:40, and defined in subjects seropositive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
|
Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Percentages of Subjects Achieving HI Titer ≥1:40 After One or Two Doses of Either QIVc, TIV1c or TIV2c in ≥4 to <18 Years
Aikaikkuna: Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity was assessed in terms of number (%) of subjects (Previously vaccinated and Not previously vaccinated) showing HI titer ≥1:40, three weeks after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c The Committee for Medicinal Products for Human Use (CHMP) criterion for an adult population was that the percentage of subjects achieving an HI titer ≥1:40 is >70%
|
Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Geometric Mean Ratios (GMR) in Subjects After One or Two Doses of Either QIVc, TIV1c or TIV2c in ≥4 to <18 Years Age
Aikaikkuna: Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity was measured in subjects (Previously vaccinated and Not previously vaccinated) as the geometric mean ratio (GMR).
The ratio of postvaccination to prevaccination HI GMTs, three weeks after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c .For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c The CHMP criterion for GMR in adult population is >2.5
|
Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
GMT in Subjects After Receiving One or Two Doses of Either QIVc, TIV1c Against B2 Strain
Aikaikkuna: Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity of QIVc to comparator TIV1c was assessed in terms of GMT in subjects (Previously vaccinated and Not previously vaccinated) measured by HI assay, three weeks after last vaccination with one or two doses of either QIVc or TIV1c. Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV1c /GMT QIVc) for HI antibody did not exceed the superiority margin of 1 |
Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Percentages of Subjects Achieving Seroconversion Against B2 Strain After One or Two Doses of Either QIVc or TIV1c
Aikaikkuna: Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity of QIVc to comparator TIV1c in terms of number (%) of subjects (Previously vaccinated and Not previously vaccinated) showing seroconversion or significant increase in HI antibody titers, against influenza strain B2, three weeks after last vaccination with QIVc or TIV1c. Superiority criterion was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c - % seroconversion QIVc) for HI antibody does not exceed the margin of 0 points |
Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
GMT in Subjects After Receiving One or Two Doses of Either QIVc,TIV2c Against B1 Strain
Aikaikkuna: Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity of QIVc to comparator TIV2c was assessed in terms of GMT in subjects (Previously vaccinated and Not previously vaccinated) measured by HI assay, three weeks after last vaccination with one or two doses of either QIVc or TIV2c. Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV2c /GMT QIVc) for HI antibody does not exceed the superiority margin of 1 |
Day 1, Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Percentages of Subjects Achieving Seroconversion After One or Two Doses of Either QIVc or TIV2c
Aikaikkuna: Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
Immunogenicity of QIVc to comparator TIV2c in terms of number (%) of subjects (Previously vaccinated and Not previously vaccinated) showing seroconversion or significant increase in HI antibody titers, against influenza strain B1, three weeks after last vaccination with QIVc or TIV2c. Superiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV2c - % seroconversion QIVc) for HI antibody does not exceed the margin of 0 points |
Three weeks post vaccination (Day 22 for previously vaccinated and Day 50 for Not previously vaccinated subjects)
|
|
Number of Subjects Reporting Solicited Adverse Events (AEs) After One or Two Doses of Either QIVc, TIV1c or TIV2c by Age Sub-strata
Aikaikkuna: Day 1 to 7 after last vaccination
|
Safety was assessed in terms of number of subjects (Previously vaccinated and Not previously vaccinated) reporting solicited local and systemic reactions, day 1 to 7 after last vaccination with one or two doses of either QIVc, TIV1c or TIV2c.For A/H1N1, A/H3N2 and B1 strain, the comparison was between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c.
|
Day 1 to 7 after last vaccination
|
|
Number of Subjects Reporting Unsolicited AEs After One or Two Doses of Either QIVc, TIV1c or TIV2c by Overall Age Group
Aikaikkuna: Day 1 to 210 post vaccination
|
Safety was assessed in terms of number of subjects (Previously vaccinated and Not previously vaccinated) reporting unsolicited AEs (day 1 to 22 for Previously vaccinated and day 1 to day 50 for Not previously vaccinated subjects), serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, new onset of chronic diseases (NOCDs), and concomitant medications (day 1 to day 181 for Previously vaccinated and day 1 to day 210 for Not previously vaccinated subjects) after receiving one or two doses of either QIVc, TIV1c or TIV2c.
For A/H1N1, A/H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison was between QIVc and TIV2c.
|
Day 1 to 210 post vaccination
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- V130_03
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .